U.S. markets open in 13 minutes

Synlogic, Inc. (SYBX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.7800-0.2500 (-6.20%)
At close: 4:00PM EST

3.6500 -0.13 (-3.44%)
Pre-Market: 9:05AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close4.0300
Open4.1500
Bid0.0000 x 800
Ask4.9500 x 1000
Day's Range3.7400 - 4.2700
52 Week Range1.3500 - 5.1100
Volume331,908
Avg. Volume1,600,888
Market Cap148.679M
Beta (5Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-1.6420
Earnings DateMar 10, 2021 - Mar 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Synlogic to Present at Upcoming Virtual Banking and Industry Conferences
    PR Newswire

    Synlogic to Present at Upcoming Virtual Banking and Industry Conferences

    Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan, M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other members of the executive team will present at the following virtual banking and industry conferences:

  • Synlogic Appoints Lisa Kelly-Croswell to its Board of Directors
    PR Newswire

    Synlogic Appoints Lisa Kelly-Croswell to its Board of Directors

    Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Lisa Kelly-Croswell to its board of directors.

  • Joint Team from MIT and Synlogic Named a Biotechnology Grand Challenge Winner by Air Force Research Laboratory
    PR Newswire

    Joint Team from MIT and Synlogic Named a Biotechnology Grand Challenge Winner by Air Force Research Laboratory

    A collaboration between MIT Voigt Lab and Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, has been recognized by the Air Force Research Laboratory (AFRL) as a Biotechnology Grand Challenge Winner. One of four winning teams, the joint team comprised of MIT and Synlogic was awarded $1 million in an effort to spearhead innovation among small businesses in the field of biotechnology for the Department of Defense.